A case report of haploidentical hematopoietic stem cell transplantation for diffuse large B-cell lymphoma developing in the course of immunosuppressive therapy after kidney transplantation

Abstract

Post-transplant lymphoproliferative disease (PTLD) is one of the most common complications after organ transplantation. The main goal of PTLD treatment is to achieve stable remission of the disease and preserve the transplanted organ. However, it is not uncommon that after PTLD therapy immunosuppressive therapy for the transplanted organ is returned, which may again lead to a recurrence of PTLD. Autologous hematopoietic stem cell transplantation is a rare option for treatment PTLD. The role of allogeneic hematopoietic stem cell transplantation (HSCT) in PTLD therapy after solid organ transplantation has not been determined, due to the high risks of toxicity for the transplanted organ, the develop-ment of a graft-versus-host disease may lead to rejection of the transplanted solid organ, and the presence of a solid organ transplant may increase the rejection of he-matopoietic stem cells.We have described a case report of haploidentical he-matopoietic allogeneic stem cell transplantation with TCR αβ+/CD19+ cell depletion for a patient with sec-ond remission of diffuse large B-cell lymphoma associated with immunosuppressive therapy for a previously performed allogeneic cadaveric kidney transplantation.